Cerulean, Novartis to develop drug conjugates

Cerulean Pharma Inc. (NASDAQ:CERU) gained $0.27 (40%) to $0.95 after announcing a deal with Novartis

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE